AVCTAvacta Group Plc
70.00GBP+2.19%Mkt Cap: 411.66M $P/E:

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug co…

Key Statistics

Company
Market Cap411.66M $
Enterprise Value400.82M $
Revenue (TTM)144.93K $
Gross Profit144.93K $
Net Income (TTM)-49.52M $
Revenue/Share0.0000 USD
Last Price70.00 GBP
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees81
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-10.50
PEG
EV/EBITDA-10.72
EV/Revenue2765.50
P/S2794.56
P/B112.33
EPS (TTM)-0.09
EPS (Forward)-0.06
52W Range
0.000076% of range92.00
52W High92.00 GBP
52W Low0.0000 GBP
Profitability
Gross Margin100.00%
Oper. Margin-28680.70%
EBITDA Margin0.00%
Profit Margin-34169.91%
ROE-1559.45%
ROA-131.26%
Growth
Revenue Growth0.00%
Earnings Growth
Cash Flow & Leverage
Operating CF-34.35M $
CapEx (TTM)67.98K $
FCF Margin-3617.37%
FCF Yield-1.27%
Net Debt1.09M $
Net Debt/EBITDA-0.03
Balance Sheet
Debt/Equity6.02
Current Ratio0.89
Quick Ratio0.84
Book Value/Sh0.0060 GBP
Cash/Share0.0370 GBP
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 GBP
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split1:100
Split DateJan 26, 2016
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)81.67 GBP
Upside (mean)+16.7%
Target Range60.00 GBP101.00 GBP
GBP60.00+16.7% to meanGBP101.00
# Analysts3
Ownership
Shares Out.468.55M
Float427.17M
Insiders2.90%
Institutions8.32%
Technical
SMA 5069.61 (+0.6%)
SMA 20068.84 (+1.7%)
Beta-0.11
S&P 52W Chg18.16%
Avg Vol (30d)765.36K
Avg Vol (10d)758.06K
Technical Indicators
RSI (14)51.3
MACD-1.2986
MACD Signal-1.4571
MACD Hist.+0.1585
BB Upper71.01 GBP
BB Middle67.39 GBP
BB Lower63.78 GBP
BB Width10.72%
ATR (14)3.519 GBP
Vol Ratio (20d)2.19x